albumin - publications

Predict more albumin - ligand interactions now!


1. Expert Opin Pharmacother. 2012 Feb;13(3):395-406. Epub 2012 Jan 21.

Enhancing intracellular taxane delivery: current role and perspectives of
nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

Guarneri V, Dieci MV, Conte P.

University of Modena and Reggio Emilia, University Hospital, Department of
Oncology, Hematology and Respiratory Diseases , Via del Pozzo 71, Modena 41100 ,
Italy +39 059 422 3299 ; +39 059 422 4429 ; conte.pierfranco@unimore.it.

Introduction: Docetaxel and paclitaxel are among the most active agents for the
treatment of breast cancer. These first-generation taxanes are extremely
hydrophobic; therefore, solvents are needed for its parenteral administration.
Albumin nanoparticle technology allows for the transportation of such hydrophobic
drugs without the need of potentially toxic solvents. Nab-paclitaxel can be
administered without premedication, in a shorter infusion time and without the
need for a special infusion set. Moreover, this technology allows the selective
delivery of larger amounts of anticancer drug to tumors, by exploiting endogenous
albumin pathways. Areas covered: An overview of the albumin nanoparticle
technology, from a clinical perspective, is reported in this paper. The
preclinical and clinical development of nab-paclitaxel is reviewed, in the
context of available therapies for advanced breast cancer, with a focus on safety
data. Preclinical and clinical data on the prognostic and predictive role of
SPARC (secreted protein, acidic and rich in cysteine) are also reported. Expert
opinion: Nab-paclitaxel is approved at present for the treatment of metastatic
breast cancer, after the failure of first-line standard therapy, when
anthracyclines are not indicated. Efficacy and safety data, along with a more
convenient administration, confirm the potential for nab-paclitaxel to become a
reference taxane in breast cancer treatment.

PMID: 22263900 [PubMed - in process]